Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.

Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to wipe out ...

In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...

Danish leader will face a challenging landscape among competitors ...

Altria shares are on pace for their highest close in over six years after the company lifted its profit outlook and said strong demand for its oral nicotine pouches is helping to offset declining ...

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

NVO has been struggling on the charts since its late-April bottom at $57, with recent pressure at the $70 region. So far in ...

Novo Nordisk's new CEO, Maziar Mike Doustdar, is tasked with revitalizing the company's flagging sales and addressing ...

Hit by rising medical care costs and squeezed by government changes, the health care conglomerate acknowledges “pricing and operational mistakes” affected its bottom line and has outlined steps to ...